STOCK TITAN

Scienture Holdings (SCNX) Stock News

SCNX NASDAQ

Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.

Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.

Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.

Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.

Rhea-AI Summary

Scienture (SCNX) reported third-quarter 2026 revenue of $1.25 million, driven by the August commercial launch of REZENOPY nasal spray. Revenue rose approximately 265% sequentially and 113% year over year. Initial REZENOPY wholesale shipments generated approximately $925,000; Arbli contributed approximately $330,000. Gross profit rose approximately 77.5% year over year to $1.02 million, with an approximately 81.3% margin.

Quarterly net loss widened to approximately $6.0 million from approximately $3.6 million. Nine-month revenue rose approximately 176% to $1.65 million, while net loss narrowed approximately 8.6% to $12.2 million. Cash, cash equivalents and restricted cash totaled approximately $7.8 million at September 30. An exclusive REZENOPY distribution agreement provides access to approximately 2,000 treatment facilities, and the first direct-channel orders have shipped. Management targets profitability in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Scienture (SCNX) reported preliminary, unaudited third-quarter 2026 revenue of approximately $1.22 million as its two commercial products contributed sales. Revenue increased 256% sequentially from $343,639 in the second quarter, supported by Arbli growth and initial REZENOPY shipments following its August 2026 launch. Arbli wholesale unit sales rose 74% sequentially.

Second-quarter 2026 gross margin was approximately 97.7%. Operating expenses fell approximately 41% year over year to $3.0 million, while net loss narrowed approximately 58% to $2.8 million. REZENOPY group purchasing agreements provide access to more than 5,000 healthcare facilities; Arbli gained formulary additions at more than ten U.S. pediatric academic medical centers. Both products have U.S. patent protection extending into 2041. Scienture targets profitability in 2027 and expects continued sequential revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
none
-
Rhea-AI Summary

Scienture Holdings (NASDAQ: SCNX) reported preliminary, unaudited third-quarter 2026 revenue of approximately $1.22 million, reflecting growth across its commercial products. Revenue for the quarter ended September 30, 2026 increased 256% from approximately $344,000 in the second quarter. The increase reflected continued Arbli sales growth and initial wholesale shipments following REZENOPY's August 2026 commercial launch.

Arbli wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting commercial expansion. REZENOPY became Scienture's second commercial-stage FDA-approved product. The company expects to accelerate revenue growth through the remainder of 2026 and into 2027, and targets profitability in 2027 while expanding distribution and commercial adoption. The revenue figures remain subject to customary adjustments; full quarterly results will be included in its Form 10-Q.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.14%
Tags
none
Rhea-AI Summary

Scienture Holdings (SCNX) announced that Arbli oral suspension has been added to formularies at three U.S. pediatric academic medical centers and hospitals. These institutions specialize in treating children with complex and chronic medical conditions. The additions expand Arbli’s presence in institutional and pediatric healthcare.

Wholesale orders are increasing sequentially as the commercial rollout continues. Arbli is a ready-to-use liquid formulation of losartan that does not require pharmacy compounding. The U.S. losartan market represents approximately $219 million in sales and approximately 72 million prescriptions annually, based on IQVIA MAT April 2026 data. Scienture plans to pursue further hospital formulary placements while expanding payer coverage, pharmacy availability and distribution access nationwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.33%
Tags
none
-
Rhea-AI Summary

Scienture Holdings (SCNX) announced a 1-for-25 reverse stock split expected to take effect before markets open on October 5, 2026.

Split-adjusted trading on the Nasdaq Capital Market will begin that day under the unchanged symbol. Shares issued and outstanding totaled 41,064,146 as of September 30, 2026; the company expects approximately 1,642,565 after the split. Scienture intends the split to support compliance with Nasdaq’s minimum bid price requirement and make additional shares available for future issuance.

The authorized share count will remain unchanged. Ownership percentages will remain unchanged except for fractional shares, which will be paid in cash rather than issued.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.83%
Tags
-
Rhea-AI Summary

Scienture Holdings (SCNX)/b) announced that subsidiary Scienture, LLC has entered an exclusive U.S. sales, marketing and distribution agreement for REZENOPY™ (naloxone hydrochloride nasal spray 10 mg/0.11 mL) with a distribution partner serving addiction treatment providers.Under the agreement, REZENOPY will be available only through the partner’s network of approximately 2,000 Opioid Treatment Program clinics and other addiction treatment centers, while Scienture continues to sell through wholesalers, GPOs and other channels outside this field. The company describes REZENOPY as the highest-dose FDA-approved naloxone nasal spray in the United States for emergency treatment of known or suspected opioid overdose. IQVIA data for MAT July 2026 show the U.S. naloxone market at about $140 million in annual sales across 9.8 million units, underscoring the commercial opportunity. Scienture’s subsidiary holds exclusive U.S. commercialization rights to REZENOPY following FDA approval on April 19, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
none
Rhea-AI Summary

Scienture (SCNX) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 in New York City.

Management plans to discuss commercial momentum for Arbli (losartan potassium) Oral Suspension and the Q3 2026 commercial launch of REZENOPY (naloxone HCl) Nasal Spray 10 mg, the company’s second FDA-approved commercial product. Scienture reports Q2 2026 revenue of approximately $344,000, up about 510% sequentially, with gross margin around 98%, and cites a strengthened cash position and more disciplined operating expenses as it works toward a goal of profitability in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Summary

Scienture (NASDAQ: SCNX) reported Q2 2026 revenue of $343,639, an approximately 510% sequential increase from $56,325 in Q1 2026. Q2 gross profit was $335,779, implying a gross margin of about 97.7%, while first-half 2026 revenue rose to $399,964 from $10,258 a year earlier.

Q2 2026 operating expenses declined roughly 41% year-over-year to about $3.0 million, improving operating loss to approximately $2.7 million. Net loss narrowed about 58% year-over-year to $2.8 million, or $0.07 per share. Cash, cash equivalents and restricted cash totaled roughly $11.2 million at June 30, 2026.

The company commenced the commercial launch of REZENOPY™, its second commercial product, and expanded payer access for Arbli™, adding around 12.5 million covered lives. The USPTO granted additional patents for both products, extending expected intellectual property protection and market exclusivity through 2041.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
Rhea-AI Summary

Scienture (NASDAQ: SCNX) announced the commercial launch of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg and fulfillment of its first U.S. wholesaler purchase orders, marking nationwide distribution of its second FDA-approved commercial product.

REZENOPY™ is described as the highest-dose FDA-approved naloxone nasal spray in the U.S., delivering 10 mg in a single-use device for emergency treatment of known or suspected opioid overdose. According to Scienture, launch execution is supported by a dedicated national sales force, payer coverage potentially reaching more than 100 million covered lives, and GPO agreements providing commercial access to over 5,000 healthcare facilities, representing potential penetration of more than 60% of the U.S. institutional naloxone market. Based on IQVIA data (MAT June 2026), the U.S. naloxone market generated about $143 million in annual sales across roughly 9.8 million units, which Scienture highlights as a substantial commercial opportunity. The product is supplied as two single-spray intranasal devices per carton and includes detailed safety, administration, contraindication, and storage information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.00%
Tags
none
Rhea-AI Summary

Scienture (NASDAQ: SCNX) completed commercial launch inventory and will begin July 2026 shipments of REZENOPY (naloxone hydrochloride) Nasal Spray 10 mg to U.S. wholesalers, with commercial availability expected in August.

REZENOPY is the highest-dose FDA-approved naloxone nasal spray in the U.S., targeting a ~$144 million, 9.8 million-unit annual naloxone market. Scienture reports payer access potential above 100 million covered lives and holds exclusive U.S. commercialization rights following FDA approval on April 19, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none

FAQ

What is the current stock price of Scienture Holdings (SCNX)?

Scienture Holdings (SCNX) last closed at $2.90.

What is the market cap of Scienture Holdings (SCNX)?

The market cap of Scienture Holdings (SCNX) is approximately $4.8M.